Customer Spotlight: Fueling The Progression Of An Innovative Cystic Fibrosis Treatment With A Strong Culture Match

Innovative complex biologics are offering new hope to patients with genetic diseases once thought untreatable. Yet bringing these therapies from preclinical research to clinical and commercial stages is highly complex and often depends on the expertise of a contract manufacturing organization (CMO) with the right cultural alignment.

One biotech company, dedicated to advancing the next generation of genetic medicines through superior drug delivery, turned to Pfizer CentreOne to support the development of its groundbreaking cystic fibrosis (CF) therapy. By fostering a transparent, collaborative partnership built on communication and a shared commitment to transforming patients’ lives, the two teams successfully advanced the therapy into Phase 1 clinical trials — bringing patients one step closer to a much-needed treatment.